Gilead Sciences Receives $210 Million Venture Capital Funding to Expand Trodelvy’s Application in Non-Small Cell Lung Cancer (NSCLC)

1. Gilead Sciences has secured a substantial investment of $210 million from venture capital sources.
2. The funding is aimed at expanding the clinical case for Trodelvy® (sacituzumab govitecan), an antibody-drug conjugate developed by Immunomedics, which was acquired by Gilead in 2020.
3. Trodelvy is currently approved as a single agent for adult patients with metastatic triple-negative breast cancer who have received two or more prior systemic therapies.
4. With this funding, Gilead plans to broaden Trodelvy's application into non-small cell lung cancer (NSCLC).
5. The venture capital investment will support ongoing studies evaluating Trodelvy across various lines of treatment and combinations in advanced NSCLC, including Phase III trials like ASCENT-Lung 01 and DESTINY-Lung04.
6. This financial boost is expected to accelerate the development of Trodelvy as a potential therapeutic option for NSCLC patients.